How should clinicians address intratumour heterogeneity in clear cell renal cell carcinoma?
More about Open Access at the CrickAbstract
Despite the availability of multiple targeted therapies, the 5-year survival rate of patients with metastatic clear cell renal cell carcinoma (ccRCC) rarely exceeds 10%. Recent insights into the mutational landscape and evolutionary dynamics of ccRCC have offered up a plausible explanation for these outcomes. The purpose of this review is to link the research findings to potential changes in clinical practice.
Journal details
Journal Current Opinion in Urology
Volume 25
Issue number 5
Pages 358-366
Available online
Publication date
Full text links
Publisher website (DOI) 10.1097/mou.0000000000000204
Europe PubMed Central 26125509
Pubmed 26125509
Keywords
Related topics
Type of publication